Gastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks
Conditions
Keywords
Gastric cancer, Her2/neu, Dual paraffin blocks, Trastuzumab, Clinical Prospective Multicenter Cohort Study
Brief summary
Background: Gastric cancer (GC) is major global health concern and the second leading cause of cancer deaths worldwide. Amplification of Her2/neu gene and/or overexpression of the Her2/neu protein have been observed in GC. Trastuzumab (Herceptin™) is an anti-Her2/neu antibody, which has been successfully applied in GC. However, the intratumoral heterogeneity of Her2/neu overexpression and amplification in GC should be noticed. The investigators investigated the significance of evaluating Her2/neu expression in different paraffin blocks of tumor tissue in GC. Methods: 2000 GC patients from ten centers, patients were divided into a cohort using one tumor tissue paraffin block (cohort 1, n=1000) and a cohort using dual tumor tissue paraffin blocks (cohort 2, n=1000) when evaluating Her2/neu expression status by immunohistochemistry (IHC). In cohort 2, the investigators combined the results from two different paraffin blocks and used the higher one as the final score.
Interventions
PROCEDUREchoose two tumor tissue paraffin blocks
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Undergone curative surgery of gastric cancer, * 18-80 years old.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| compare the positive rate | 3 years |
Outcome results
None listed